Shares of Fulgent Genetics FLGT moved higher by 24.0% in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05.
Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000.
Guidance
Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est.
Details Of The Call
Date: Mar 04, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/jf6vsajc
Technicals
52-week high: $189.89
52-week low: $6.70
Price action over last quarter: Up 246.36%
Company Profile
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
